(-)-Pteroside N and pterosinone, new BACE1 and cholinesterase inhibitors from Pteridium aquilinum
- Authors
- Choi, Yun-Hyeok; Choi, Chun Whan; Kim, Jin Kyu; Jeong, Wonsik; Park, Gil Hong; Hong, Seong Su
- Issue Date
- 10월-2018
- Publisher
- ELSEVIER SCIENCE BV
- Keywords
- Pteridium aquilinum; Bracken; Seco-illudoid; BACE1; Cholinesterase
- Citation
- PHYTOCHEMISTRY LETTERS, v.27, pp.63 - 68
- Indexed
- SCIE
SCOPUS
- Journal Title
- PHYTOCHEMISTRY LETTERS
- Volume
- 27
- Start Page
- 63
- End Page
- 68
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/72544
- DOI
- 10.1016/j.phytol.2018.06.021
- ISSN
- 1874-3900
- Abstract
- Bioassay-guided fractionation of the ethanolic extract from the whole plants of Pteridium aquilinum has resulted in the isolation of a new pterosin glycoside, (-)-pteroside N (1), and a new seco-illu doi d sesquiterpene, pterosinone (2). Their structures were identified by analysis of the spectroscopic data including extensive 2D NMR. All of the isolates were evaluated for the anti-Alzheimer disease (anti-AD) activity through enzyme inhibition of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1). (-)-Pteroside N (1) showed moderate BACE1 inhibitory activity (IC50 value: 30.6 mu M), but exhibited potent inhibitory activity against AChE and BChE (IC50 values: 4.47 and 7.39 mu M, respectively). On the other hand, pterosinone (2) showed mild AChE and BChE inhibitory activity (IC50 value: 87.7 and 72.9 mu M), but exhibited potent inhibitory activity against BACE1 (IC50 value: 19.4 mu M). The results of the present study demonstrate that sesquiterpenoids from P. aquilinum might be beneficial in the treatment of AD.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.